A message from the NIH National Institute of Allergy and Infectious Diseases (NIAID).

The NIAID has posted a video describing the development of HIV vaccine candidates and the launch of the NIAID-supported HVTN 702 clinical trial, the first new HIV vaccine efficacy study in seven years. HVTN 702 is testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The regimen involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.

 Click here to watch the video.